At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
LY3007113drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating LY3007113 for Metastatic Cancer. Completed, enrolled 27 participants across 2 sites.
Detailed Summary
This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionDec 2013
TodayJul 2026
First PostedNov 2, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.7 years ago
Interventions
LY3007113drug
Administered orally